
Last updated: 2026-09-06 09:43:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PMV Pharmaceuticals, Inc. (PMVP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,29, with a market capitalization of $67,36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,02 to $1,88. This page covers its latest market performance, valuation, price trends and company information.
$67,36M | |
$1,24 | |
$63,22 | |
$0,81 | |
$1,24 | |
522,68K | |
-- | |
-- | |
$1,88 | |
$1,02 | |
-- | |
-- |
PMV Pharmaceuticals, Inc. (PMVP) last closed at $1,24 as of 2026-09-04 23:34:00, unchanged from the previous close of $1,24.
During the latest regular trading session, PMVP traded between $0,81 and $63,22, with a volume of 522,68K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, PMV Pharmaceuticals, Inc. (PMVP) moved from $1,24 to $1,29, representing a gain of 3,63% ($0,04).
The stock traded between $1,24 and $1,35 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1,43 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30,8%
PMVP is currently trading at $1,29, placing it 30,8% of the way from its 52-week low of $1,02 to its 52-week high of $1,88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 54 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PMV Pharmaceuticals, Inc. (PMVP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.